Flurandrenolide

證據等級: L5

預測適應症: 10 個

Flurandrenolide: From No Documented Indication to Vulvar Inverted Follicular Keratosis

One-Sentence Summary

Flurandrenolide currently has no recorded approved indications, no US/Taiwan marketing licenses, and no verified mechanism-of-action data in this evidence pack. The TxGNN model’s top-ranked prediction is Vulvar Inverted Follicular Keratosis (score 99.71%), but this is supported by 0 clinical trials and 0 publications, and the model’s own rationale states the mechanism does not plausibly fit this lesion type.

Quick Overview

Item	Content
Original Indication	Not documented (no approved indications on record; drug not currently marketed)
Predicted New Indication	Vulvar Inverted Follicular Keratosis
TxGNN Prediction Score	99.71%
Evidence Level	L5 (model prediction only, no supporting trials or literature)
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for flurandrenolide is a confirmed data gap in this evidence pack. However, the model’s own rationale text for other candidates in this list characterizes flurandrenolide as a mid-potency topical corticosteroid with anti-inflammatory and immunomodulatory activity — this is embedded evidence-pack context, not an external claim.

For the top-ranked prediction itself, this mechanism does not hold up: vulvar inverted follicular keratosis is a benign follicular epithelial proliferative lesion (tumor-like), not an inflammatory or immune-mediated condition. The pack’s own repurposing rationale is explicit that a topical corticosteroid’s anti-inflammatory mechanism has no direct relevance to this pathology, and no clinical or literature evidence exists to support it. This is why the associated decision stage is S0 with a “Hold” recommendation, despite the high raw TxGNN score.

By contrast, several lower-ranked but mechanistically stronger candidates appear in the same prediction set: lichen planus pigmentosus, hypertrophic lichen planus, annular atrophic lichen planus, lichen planus pemphigoides, alopecia areata, and alopecia mucinosa are all T-cell/immune-mediated inflammatory dermatoses for which topical or intralesional corticosteroids are an established treatment class. These are flagged as decision stage S1 (“Research Question”) rather than S0, reflecting stronger class-effect biological plausibility — though still with zero drug-specific trial or literature evidence for flurandrenolide by name. A high TxGNN score alone does not guarantee mechanistic fit; in this case the rank-1 prediction is the weakest of the ten candidates on mechanistic grounds.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

Flurandrenolide currently has no marketing authorizations on record (0 licenses; market status: Not Marketed).

Safety Considerations

Please refer to the package insert for safety information.

(Note: label warnings/contraindications and DDI data are both marked as data gaps in this evidence pack — see Conclusion for remediation.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (vulvar inverted follicular keratosis) has no clinical, literature, or credible mechanistic support — evidence level L5 with an explicit mechanistic mismatch noted in the model’s own rationale. In addition, a Blocking data gap (TFDA label warnings/contraindications, DG001) prevents this candidate from even entering a preliminary S1 safety screen.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain TFDA label warnings/contraindications
Resolve DG002 (High): confirm mechanism of action via DrugBank API
If pursuing repurposing further, re-scope toward the lichen planus–spectrum candidates (ranks 2–4) or alopecia areata (rank 5), which carry stronger class-effect mechanistic rationale, and commission a targeted literature/trial search specific to flurandrenolide (not just the corticosteroid class) in those indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.